InvestorsHub Logo
Followers 4
Posts 497
Boards Moderated 0
Alias Born 08/09/2017

Re: None

Tuesday, 10/17/2017 12:59:57 PM

Tuesday, October 17, 2017 12:59:57 PM

Post# of 55131
Sites Confusing XXII Investors with Fake Price Target

Yesterday, Chardan's James McIlree reiterated a 'buy' rating on shares of 22nd Century Group, Inc. (NYSE:XXII) alongside a price target of $11.50 per share. While the term fake news is usually used by President Trump, it's the most fitting term to describe some of the XXII-related articles we've seen floating around today.

The report called 22nd Century Group "the solution to big tobacco's $30B problem." Chardan's "$11.50 price target is based on the company garnering royalty revenue for its technology on 10% of the US market share in the next five years." Risks to achieving the target price include "delays in the FDA process, ability to find partners for X-22, challenges in attracting contract manufacturing and selling product overseas and possibility of requiring additional capital."

REST OF THE ARTICLE
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent XXII News